{"filings":[{"id":95661,"accession_number":"0001193125-26-213380","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.","Cash $169.1M at March 31, 2026; expects to fund operations through first half of 2028.","Phase 1b/2 evorpacept + zanidatamab data: 60% cORR in ccHER2+ patients; all 5 with high CD47 responded (mPFS 22.1 months).","Phase 2 ASPEN-09-Breast topline data in mid-2027; Phase 1 ALX2004 safety data in 2H 2026.","Appointed Jeff Knight as Chief Development and Operating Officer in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95660,"accession_number":"0001193125-26-152050","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.","Compensation: $565k base salary, 40% annual target bonus, and stock option for 800k shares under 2025 Inducement Plan.","Knight brings 30+ years experience; previously at Poseida, Halozyme, Amgen, and Genentech.","Company highlights upcoming catalysts for evorpacept and ALX2004 programs in next 12-18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108877,"accession_number":"0001193125-26-079342","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q4 GAAP net loss $22.8M ($0.42/sh), completes $150M offering, cash runway to 1H 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $48.3M at Dec 31, 2025; after Feb 2026 $150M offering net $140.4M, runway through 1H 2028.","GAAP net loss Q4 2025 ($22.8M)/($0.42) vs ($29.2M)/($0.55) in Q4 2024; full year ($101.7M)/($1.90) vs ($134.9M)/($2.58).","R&D expenses Q4 2025 $17.6M vs $23.5M in Q4 2024; full year $77.0M vs $116.4M.","Barbara Klencke appointed permanent CMO; completed $150M registered equity offering in Feb 2026.","Clinical milestones: evorpacept biomarker data; ASPEN-09 enrollment expanded to 120 pts, topline mid-2027; ALX2004 safety data 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108876,"accession_number":"0001193125-26-030579","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.","Offering led by new investors RA Capital Management and TCGX, with participation from existing investors.","Net proceeds to fund evorpacept and ALX2004 clinical trials, working capital.","Expected close on or about Feb 2, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108875,"accession_number":"0001193125-26-030561","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.","Phase 1b/2 trial data show CD47 expression is predictive of evorpacept response in HER2+ metastatic breast cancer.","In 9 confirmed HER2+ patients, cORR was 56% (5/9) with median PFS of 7.4 months (prior SABCS2024 data).","Full biomarker analysis submitted for presentation at an upcoming scientific conference.","Results align with ASPEN-06 gastric cancer trial, strengthening confidence in ongoing ASPEN-09-Breast Phase 2 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108874,"accession_number":"0001193125-26-018094","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ALX Oncology increases inducement plan share reserve by 1.3M shares to total 2.8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended 2025 Inducement Equity Incentive Plan to reserve an additional 1,300,000 shares of common stock.","Total shares reserved under the inducement plan now 2,800,000.","Amendment adopted without stockholder approval per Nasdaq inducement award exception rules.","Awards under the plan will be granted only to new employees as material inducement to join the Company.","Plan terms are substantially similar to the Amended and Restated 2020 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125333,"accession_number":"0001193125-25-271112","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q3 net loss improves to $0.41/share; highlights evorpacept benefit in CD47-high gastric cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.","Cash, cash equivalents and investments at Sept 30, 2025: $66.5M; runway into Q1 2027.","ASPEN-06 exploratory analysis: In CD47-high retained HER2+ gastric cancer, evorpacept combo achieved 65.0% ORR vs 26.1% for control; median DOR 25.5 vs 8.4 months.","Phase 1 ALX2004 (EGFR-targeted ADC) cleared first dose cohort; currently enrolling 2 mg/kg dose; initial safety data expected 1H 2026.","Barbara Klencke, M.D., appointed interim Chief Medical Officer; brings 30+ years oncology drug development experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142048,"accession_number":"0001810182-25-000006","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ALX Oncology: CMO Alan Sandler resigns, Barbara Klencke appointed Interim CMO; Nasdaq compliance regained","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.","Barbara Klencke steps down from Board to become Interim CMO effective Sep 17, 2025.","ALX regained Nasdaq minimum bid price compliance (closing bid >= $1 for 10 consecutive days through Sep 4, 2025).","Board committee changes: R&D committee paused; new Audit, Compensation, and Governance committee assignments approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142047,"accession_number":"0000950170-25-107277","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"ALX Oncology Q2 net loss $25.9M; cash runway into Q1 2027; CD47 biomarker data highlights evorpacept potential","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.","Cash, equivalents & investments $83.5M; runway extended into Q1 2027 after pausing ASPEN-CRC trial.","ASPEN-06 analysis: CD47-high HER2+ gastric cancer patients had 65% ORR with evorpacept + TRP vs 26% TRP alone; full data Q4 2025.","ASPEN-Breast amended to single-arm biomarker-driven study; interim data expected Q3 2026.","ALX2004 Phase 1 first patient dosing in August 2025; initial safety data 1H2026. Allison Dillon appointed COO; Daniel Curran appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160023,"accession_number":"0000950170-25-085364","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ALX Oncology stockholders elect directors, approve advisory pay vote, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Scott Garland (23.6M for) and Barbara Klencke (30.8M for) elected as Class II directors to serve until 2028 annual meeting.","Advisory vote on named executive officer compensation approved: 22.1M for, 8.7M against, 1.4M abstain.","KPMG LLP ratified as independent auditor for fiscal year 2025: 41.8M for, 0.06M against, 2.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160022,"accession_number":"0000950170-25-066440","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.","Received IND clearance from FDA for ALX2004, a novel EGFR-targeted ADC; Phase 1 initiation expected mid-2025 with initial safety data in 1H 2026.","Will not pursue U.S. registrational path for evorpacept in gastric cancer after FDA feedback that accelerated approval not feasible due to ENHERTU®.","Discontinued evorpacept in combination with PADCEV® in urothelial cancer due to lack of improved efficacy in ASPEN-07 trial.","Expect to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies mid-2025, with data milestones in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160021,"accession_number":"0000950170-25-058687","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ALX Oncology receives Nasdaq bid price non-compliance notice; 180-day cure until Oct 20, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ALXO on Apr 23, 2025 that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.","Company has until Oct 20, 2025 to regain compliance by closing at or above $1.00 for at least ten consecutive business days.","If not cured, ALXO may seek a second 180-day period by transferring to the Nasdaq Capital Market, subject to eligibility.","Potential cure actions include a reverse stock split; failure to regain compliance could lead to delisting.","ALXO intends to actively monitor bid price and assess options, but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178352,"accession_number":"0000950170-25-034574","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.","Cash & equivalents $131.3M as of Dec 31, 2024; expects cash runway into Q4 2026 after ~30% workforce reduction.","ASPEN-06 Phase 2: evorpacept combo cORR 48.9% vs 24.5% control in HER2+ gastric cancer; median DOR 15.7 vs 9.1 months.","Leadership changes: appointed CBO, CMO, CFO; founder Jaume Pons steps down as President, becomes Senior Scientific Advisor.","Upcoming catalysts: ASPEN-03/04 HNSCC topline data Q2 2025; regulatory guidance on gastric cancer path Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178351,"accession_number":"0000950170-25-033504","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.","Estimated $2.2 million in severance and benefits costs, recognized in Q1 2025.","President and CSO Jaume Pons will depart in April 2025; eligible for annual salary and 12 months COBRA.","No replacement named; position eliminated; transition consulting agreement expected.","Reduction part of pipeline prioritization and cash preservation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178350,"accession_number":"0000950170-25-007532","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.","Barbara Klencke, M.D. and Chris Takimoto, M.D., Ph.D. appointed to Board effective Jan 18, 2025; each receives initial option for 40,400 shares.","Shantharam previously CFO of CymaBay ($4.3B Gilead acquisition); held finance roles at Gilead and Amgen.","Klencke serves on boards of Xencor, TScan, Immune-Onc; Takimoto is CMO at START Center, former CMO at Forty Seven ($4.9B Gilead acquisition).","Board expanded to 6 members; new committee assignments: Klencke on Audit/R&D, Takimoto on Compensation/R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178349,"accession_number":"0001193125-25-008461","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ALX Oncology adopts 2025 Inducement Plan, reserves 1.5M shares for new-hire equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Inducement Plan on Jan 16, 2025; effective immediately.","1,500,000 shares of common stock reserved for issuance under the plan.","Awards are limited to new employees as a material inducement to join the company, per Nasdaq Listing Rule 5635(c)(4).","Plan terms are substantially similar to ALX's existing 2020 Equity Incentive Plan.","No shareholder approval was required for adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195010,"accession_number":"0000950170-24-126749","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.","Former CFO Peter Garcia resigned Nov 8, 2024; receives $479,646 lump sum, COBRA for 12 months, accelerated equity vesting, and consulting role.","Board reduced to 4 directors; committees set: Audit (Hemrajani chair), Compensation (Goodman chair), Governance (Garland chair).","Dr. Sandler brings 30+ years experience from Mirati, Genentech, Zai Lab; will lead evorpacept development into late-stage trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195009,"accession_number":"0000950170-24-123252","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.","R&D expenses fell to $26.5M from $45.8M YoY; cash $162.6M sufficient into Q1 2026.","Evorpacept ASPEN-06 Phase 2 gastric/GEJ cancer showed 40.3% ORR vs 26.6% control; median duration 15.7 months.","CFO Peter Garcia resigns effective Nov 8; Shelly Pinto (SVP Finance, CAO) appointed interim CFO.","Upcoming milestones: Phase 3 registrational trial for evorpacept in gastric/GEJ mid-2025; SABCS breast cancer Dec 12."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195008,"accession_number":"0000950170-24-112734","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ALX Oncology CMO Sophia Randolph resigns; separation includes $503,880 and accelerated vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Sophia Randolph resigns effective Oct 11, 2024; she leaves to pursue other professional opportunities.","Separation agreement includes $503,880 lump sum payment plus COBRA coverage for up to 18 months.","Outstanding stock options and RSUs that would vest in 12 months post-separation will fully vest; options exercisable until July 11, 2026.","Company will commence a search for a new Chief Medical Officer.","She will provide transition consulting services via a consulting agreement for up to 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211295,"accession_number":"0000950170-24-093930","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.","Cash, equivalents and investments $186.2M; sufficient to fund operations into Q1 2026.","R&D expenses $34.7M (up $5.2M YoY); G&A expenses $6.9M (down $0.4M YoY).","ASPEN-06 Phase 2: Evo-TRP achieved 40.3% ORR vs 26.6% control; mDOR 15.7 vs 7.6 months in ITT.","Phase 3 registrational trial in gastric/GEJ cancer expected to initiate mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211294,"accession_number":"0000950170-24-091938","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.","Jaume Pons (President/CSO) and Sophia Randolph (CMO) resign from Board to focus on executive roles; no disagreement.","Board size decreased; now 4 of 5 directors are independent, resolving prior non-compliance with Nasdaq Rule 5605(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229866,"accession_number":"0000950170-24-074258","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ALX Oncology annual meeting results: all three director nominees elected, proposals approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corey Goodman, Jason Lettmann, Sophia Randolph elected as Class I directors for terms until 2027.","Advisory vote on executive compensation approved: 40,935,354 for, 1,422,239 against, 34,391 abstain.","Ratification of KPMG as independent auditor for FY 2024 approved: 47,698,670 for, 11,338 against, 2,733 abstain.","Broker non-votes: 5,320,757 on director elections and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229865,"accession_number":"0000950170-24-056886","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.","Cash & investments $184.5M as of Mar 31; subsequent ATM raised ~$26.2M net; runway into Q1 2026.","Evorpacept + R2 in R/R B-NHL IST: ORR 94%, CRR 83% (historical R2 CRR 34%) in 20 patients.","Upcoming milestones: ASPEN-07 data at ASCO June 2; ASPEN-06 top line July 2024; Phase 3 init Q4 2024.","Appointed Allison Dillon, Ph.D., as Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229864,"accession_number":"0000950170-24-052093","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ALX Oncology loses two directors; board drops below majority independent; cure period triggered","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Nielsen resigned April 28 for health; Itziar Canamasas resigned April 30 due to new professional role.","Board reduced to six directors, only three independent, breaching Nasdaq majority requirement.","Company invokes 180-day cure period under Nasdaq Rule 5605(b)(1)(A) to restore independent majority.","Scott Garland reclassified from Class III to Class II director, effective May 1.","Audit, Compensation, and Governance committees reconstituted with Garland, Goodman, Hemrajani."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248338,"accession_number":"0000950170-24-027925","cik":1810182,"company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).","Cash, equivalents, investments $218.1M at Dec 31, 2023; runway into early 2026.","R&D expenses Q4 2023: $41.8M (up from $25.2M Q4 2022) due to more active trials.","ASPEN-06 interim: ORR 52% evorpacept combo vs 22% control; mDOR not reached vs 7.4 mo.","Anticipated milestones: ASPEN-06 top-line all 122 subjects June-July 2024; Phase 3 start Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263083984.64249995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}